CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study
- 30 September 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (10) , 1615-1621
- https://doi.org/10.1016/0959-8049(95)00340-o
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Serum markers in breast cancer managementThe Breast, 1992
- A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancerAnnals of Oncology, 1992
- Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3European Journal of Cancer and Clinical Oncology, 1991
- Use of mucin like cancer associated antigen (MCA) in the management of breast cancerBritish Journal of Cancer, 1991
- Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic diseaseCancer, 1989
- Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- High molecular weight epithelial mucins as markers in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988
- Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.Journal of Clinical Investigation, 1985
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsHybridoma, 1984
- Reporting results of cancer treatmentCancer, 1981